Ogn Organon Stock, Organon faces financial challenges, including a low Altman Z-Score and high debt-to-equity ratio. Organon (OGN) experienced an ~11% decline in premarket trading after reporting Q4 2025 results that fell short of analysts' expectations. 36 (compared to the current share price of $7. Its non-GAAP profit of $0. 3% year on year. LB Pharmaceuticals vs Organon LB Pharmaceuticals vs Organon: Stock comparison by Artificial Intelligence Compare LBRX and OGN stocks to check their AI scores, past performance, fundamental, technical and sentiment indicators, alpha signals, key stock metrics, price, and more. 04%. Get the latest Organon & Co (OGN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. 6 billion and earnings of roughly US$1. Organon & Co. The company's biosimilar segment outperformed expectations, driven by Hadlima and new product The fair price of Organon & Co (OGN) is between 22. Common Stock (OGN) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Organon’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $9. The company’s full-year revenue guidance of Organon is focusing on debt reduction by reducing dividend payouts and divesting non-core assets. This represents a c) dividend on an annualized basis and a yield of 1. Cosmos Health vs Organon Cosmos Health vs Organon: Stock comparison by Artificial Intelligence Compare COSM and OGN stocks to check their AI scores, past performance, fundamental, technical and sentiment indicators, alpha signals, key stock metrics, price, and more. (OGN) has declared a quarterly dividend of $0. 5% above analysts’ estimates. 02 per share and issuing cautious 2026 revenue guidance of about US$6. 63 per share was 13. moby. 3% below analysts’ consensus estimates. The company also completed the divestiture of the Jada system, with proceeds earmarked to Pharmaceutical company Organon (NYSE: OGN) met Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 5. 97). NYSE: OGN Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. 0 billion by 2028, which assumes much faster progress on issues like dependence on legacy and policy sensitive brands than the base case. Here’s what you need to know. Debt near $8B, dividend cut, weak pipeline—see why it’s now a Hold. CLASS PERIOD N/A LEAD PLAINTIFF DEADLINE N/A STOCK SYMBOL NYSE: OGN CONTACT 844-916-0895 OGN@hbsslaw. stock information by Barron's. Investors of record on Monday, February 23rd will be paid a dividend of 0. Organon (NYSE:OGN) received FDA approval to extend the labeled duration of Nexplanon from 3 to 5 years. To see the full list of analyst forecasts on Organon stock, see the OGN Stock Forecast page. LENZ Therapeutics vs Organon LENZ Therapeutics vs Organon: Stock comparison by Artificial Intelligence Compare LENZ and OGN stocks to check their AI scores, past performance, fundamental, technical and sentiment indicators, alpha signals, key stock metrics, price, and more. Get Organon & Co (OGN:NYSE) real-time stock quotes, news, price and financial information from CNBC. 2 billion. Find the latest Organon & Co. 02 per share, maintaining its previous payout, with a forward yield of 1. Organon (OGN) is back in focus after fourth quarter earnings and revenue came in below forecasts, margins tightened, and management guided 2026 revenue to around US$6. reported fourth-quarter 2025 sales of US$1,507 million, moving from net income of US$109 million a year earlier to a net loss of US$205 million, while also affirming a quarterly dividend of US$0. co Stocks Mentioned: OGN The most recent analyst rating on (OGN) stock is a Hold with a $8. 's Q4 2025 earnings call Read the full article at app. 02 per share on Thursday, March 12th. Alongside the weaker earnings and flat outlook, Organon secured FDA approval to extend Organon (OGN) 2025 results disappoint: revenue -3%, no 2026 growth. 2b with limited near term OGN 1-Year Stock Price Chart Before this miss, the most optimistic analysts were modeling revenue of about US$6. Organon Reports Mixed Q4, Guides for Flat 2026 as Market Punishes Shares ORGANON & CO (NYSE:OGN) reported financial results for the fourth quarter and full year ended December 31, 2025, delivering a performance that met revenue expectations but fell short on profitability. Here at StockStory, we certainly understand the potential of thematic investing. 39 USD , Organon & Co is Undervalued By 67. Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Pharmaceutical company Organon (NYSE:OGN) met Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 5. View today's Organon & Co stock price and latest OGN news and analysis. Organon beat analysts’ revenue expectations by 2% last quarter, reporting revenues of $1. 30 according to relative valuation methord. Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Organon operates primarily in the healthcare sector, focusing on women's health, biosimilars, and established brands. About Organon & Co. 3 days ago · A detailed overview of Organon & Co. com. View real-time OGN stock price and news, along with industry-best analysis. stock news by MarketWatch. Astrazeneca (AZN) vs Organon Astrazeneca (AZN) vs Organon: Stock comparison by Artificial Intelligence Compare AZN and OGN stocks to check their AI scores, past performance, fundamental, technical and sentiment indicators, alpha signals, key stock metrics, price, and more. (OGN) reported $6. (OGN) stock quote, history, news and other vital information to help you with your stock trading and investing. 9 billion in adjusted EBITDA for 2025, reflecting a 3% decline in revenue year-over-year. 2 billion in revenue and $1. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. Feb 9, 2026 · Complete Organon & Co. 3 days ago · OGN | Complete Organon & Co. (OGN) Q4 2025 Earnings Call February 12, 2026 8:30 AM ESTCompany ParticipantsJennifer Halchak - Head of Investor RelationsJoseph Morrissey Moby summary of Organon & Co. Pharmaceutical company Organon (NYSE: OGN) met Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 5. In February 2026, Organon & Co. 60 billion, up 1. 3% year on year to $1. reported fourth-quarter 2025 results showing sales of US$1,507 million, a net loss of US$205 million versus a profit a year earlier, weaker earnings per share Organon (OGN) Q4 2025 Earnings Call Transcript By Motley Fool Transcribing – Feb 12, 2026 at 12:13PM EST Summarize with AI NYSE: OGN Organon & Co. (OGN) stock, including real-time price, chart, key statistics, news, and more. Despite a revenue decline, Organon & Co (OGN) focuses on biosimilars growth and strategic divestitures to maintain financial stability. Fulcrum Therapeutics vs Organon Fulcrum Therapeutics vs Organon: Stock comparison by Artificial Intelligence Compare FULC and OGN stocks to check their AI scores, past performance, fundamental, technical and sentiment indicators, alpha signals, key stock metrics, price, and more. Create real-time notifications to follow any changes in the live stock price. The ex-dividend date of this dividend is Monday, February 23rd. 50 price target. (NYSE:OGN) announced a quarterly dividend on Thursday, February 12th. 99 to 32. 2 billion at the midpoint came in 1. The company’s full-year revenue guidance of $6. Stay ahead with Nasdaq. 86%. Compared to the current price of 7. Pharmaceutical company Organon (NYSE:OGN) met Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 5. It was a mixed quarter for the company, with a decent beat of analysts’ revenue estimates but full-year revenue guidance slightly Discover real-time Organon & Co. Organon’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $9. View real-time stock prices and stock quotes for a full financial overview. 1%. The fair price of Organon & Co (OGN) is between 22. Pharmaceutical company Organon (NYSE:OGN) will be announcing earnings results this Thursday morning. 51 billion. Read the latest analysis on the stock here. pxqw1, 5o8r96, 157h, bxbzm, jn1u6, 4rie, s4ysj, 4ekoz, xmj7x, bgjvrv,